Windtree Therapeutics ( (WINT) ) has provided an update.
Windtree Therapeutics, Inc. announced the retirement of Craig Fraser as CEO, effective December 2024, with Jed Latkin set to take over the role. Latkin, who brings extensive experience in finance and biotech from his previous roles at ProPhase Labs and other companies, will assume leadership with a focus on leveraging his expertise to drive the company forward. His compensation package includes bonuses and equity incentives, reflecting the company’s commitment to aligning executive interests with shareholder value.
For an in-depth examination of WINT stock, go to TipRanks’ Stock Analysis page.
